Research programme: anti-cancer therapeutics - Theryte

Drug Profile

Research programme: anti-cancer therapeutics - Theryte

Alternative Names: THR-53; THR-93

Latest Information Update: 06 Jul 2016

Price : $50

At a glance

  • Originator TheRyte Ltd
  • Class Peptidomimetics
  • Mechanism of Action CDC2 protein kinase modulators; Cyclin-dependent kinase 4 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Non-small cell lung cancer

Most Recent Events

  • 06 Jul 2016 Preclinical development is ongoing in United Kingdom
  • 06 Jul 2016 Anti-cancer therapeutics are available for licensing as of 06 Jul 2016. http://www.theryte.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top